Assessing cost-effectiveness in the management of multiple sclerosis
Ceri J Phillips, Ioan HumphreysInstitute for Health Research, School of Health Science, Swansea University, Swansea, Wales, UKAbstract: Multiple sclerosis (MS) is one of the most common causes of neurological disability in young and middle-aged adults, with current prevalence rates estimated to be 3...
Main Authors: | Ceri J Phillips, Ioan Humphreys |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-11-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | http://www.dovepress.com/assessing-cost-effectiveness-in-the-management-of-multiple-sclerosis-a3750 |
Similar Items
-
The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy
by: Sanja Stanisic, et al.
Published: (2019-04-01) -
Cost of managing an episode of relapse in multiple sclerosis in the United States
by: Ward Alexandra J, et al.
Published: (2003-09-01) -
Burden and cost of multiple sclerosis in Brazil.
by: Gisela Kobelt, et al.
Published: (2019-01-01) -
The cost of medication and the cost of treatment are not the same thing for multiple sclerosis
by: Yara Dadalti Fragoso
Published: (2013-08-01) -
Functional Assessment of Multiple Sclerosis
by: Amy M Yorke, et al.
Published: (2015-10-01)